Deutsche Bank
ZYNE

Deutsche Bank’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Deutsche Bank’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-200
Closed -$1K – 4479
2020
Q2 		$1K Sell
200
-7,659
-97% -$36.2K ﹤0.01% 4221
2020
Q1 		$30K Sell
7,859
-86,417
-92% -$401K ﹤0.01% 3778
2019
Q4 		$568K Buy
94,276
+87,518
+1,295% +$599K ﹤0.01% 2662
2019
Q3 		$49K Sell
6,758
-9,821
-59% -$111K ﹤0.01% 3952
2019
Q2 		$223K Buy
+16,579
New +$191K ﹤0.01% 3750
2019
Q1 		– Sell
-279,500
Closed -$830K – 5497
2018
Q4 		$830K Buy
279,500
+277,895
+17,314% +$1.52M ﹤0.01% 3011
2018
Q3 		$13K Sell
1,605
-3,589
-69% -$27.5K ﹤0.01% 5035
2018
Q2 		$51K Sell
5,194
-13,689
-72% -$140K ﹤0.01% 4778
2018
Q1 		$163K Sell
18,883
-8,370
-31% -$90.3K ﹤0.01% 4294
2017
Q4 		$340K Sell
27,253
-44,638
-62% -$512K ﹤0.01% 3787
2017
Q3 		$600K Sell
71,891
-151,317
-68% -$1.6M ﹤0.01% 3327
2017
Q2 		$3.79M Buy
+223,208
New +$4.44M ﹤0.01% 2115
2016
Q3 		– Sell
-3,943
Closed -$27K – 5277
2016
Q2 		$27K Buy
3,943
+3,441
+685% +$28.8K ﹤0.01% 4666
2016
Q1 		$4K Sell
502
-357
-42% -$2.88K ﹤0.01% 4987
2015
Q4 		$8K Sell
859
-94
-10% -$1.24K ﹤0.01% 4979
2015
Q3 		$13K Buy
+953
New +$23.4K ﹤0.01% 4899

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Deutsche Bank's ZYNE Position: Q3 2020 in Review

Deutsche Bank sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2020, closing a stake of 200 shares — an estimated $1K sold.

Deutsche Bank first reported a position in ZYNE in Q3 2015 and held it in 16 quarters. The position peaked at $3.79M in Q2 2017. 66 funds tracked by Wall St. Rank hold ZYNE as of Q3 2020.

  • Deutsche Bank reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2020 after selling out during the quarter.
  • Deutsche Bank sold 200 Zynerba Pharmaceuticals, Inc shares in Q3 2020, an estimated $1K.
  • Deutsche Bank first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2015 and held it in 16 quarters.
  • Deutsche Bank's Zynerba Pharmaceuticals, Inc position peaked at $3.79M in Q2 2017.
  • 66 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2020.

Based on Deutsche Bank's 13F filing for Q3 2020, filed 12 Nov 2020.